AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...
April 8 (Reuters) - AbbVie (ABBV.N), opens new tab has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount program. Under the 340B program, ...
Humira and Botox maker AbbVie is suing the Trump administration to get a clearer definition of who counts as an eligible patient in the government's discount drug program. Why it matters: While it ...
AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results